Donor bone marrow and transplantation tolerance: historical perspectives, molecular mechanisms and future directions (review).
The induction of transplantation tolerance, defined as the indefinite existence of an intact, functioning allograft, has been a goal of transplantation immunologists for decades because of the morbid effects of immunosuppressive drugs required to maintain graft function. One promising method of tolerance induction involves the peritransplant administration of cytoablative drugs followed by administration of a low dose of donor bone marrow cells. A subpopulation of donor bone marrow cells bearing the CD8 accessory molecule cause the functional deletion of graft reactive T cells via a CD95 dependent mechanism that also involves the cytokine TGFbeta. This interaction is bi-directional in which the bone marrow cell deletes the graft reactive T cell that recognizes it. Therefore, only T cells that recognize the donor antigens are deleted, leaving the immune response to other antigens intact. This protocol has been successfully used in rodents and an outbred large animal model. Clinical trials of donor bone marrow administration are now underway and initially indicate that administration of donor bone marrow is clinically safe.
George
J F
JF
Department of Surgery, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL 35294-0007, USA.
Goldstein
D R
DR
Thomas
J M
JM
D000818:Animals; D017209:Apoptosis / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000266:history / Q000276:immunology* / Q000639:trends; D002986:Clinical Trials as Topic; D049673:History, 20th Century; D006801:Humans; D007108:Immune Tolerance; D007165:Immunosuppression Therapy / Q000266:history / Q000379:methods*; D008213:Lymphocyte Activation; D016212:Transforming Growth Factor beta / Q000276:immunology
D016212:Transforming Growth Factor beta